The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
Abstract Background and Objectives Triple-negative breast cancer (TNBC) has a poor prognosis, and neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced TNBC. In this study, we aimed to evaluate the efficacy of adding carboplatin to NACT regarding pathological complete respon...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14252-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849311582656397312 |
|---|---|
| author | Sedat Yıldırım Tugba Başoğlu Akif Doğan Goncagul Akdağ Oguzcan Kınıkoğlu Alper Topal Ozkan Alan Ali Alper Solmaz Mustafa Gürbüz Timucin Çil Rumeysa Çolak Mesut Yılmaz Ali Kalem Nadiye Sever Nargiz Majıdova Kubilay Karakoyun Serhat Sekmek Omer Saçlı Melike Ozcelık Deniz Işık Heves Surmeli Ozlem Nuray Sever Hatice Odabas Mahmut Emre Yıldırım Nedim Turan |
| author_facet | Sedat Yıldırım Tugba Başoğlu Akif Doğan Goncagul Akdağ Oguzcan Kınıkoğlu Alper Topal Ozkan Alan Ali Alper Solmaz Mustafa Gürbüz Timucin Çil Rumeysa Çolak Mesut Yılmaz Ali Kalem Nadiye Sever Nargiz Majıdova Kubilay Karakoyun Serhat Sekmek Omer Saçlı Melike Ozcelık Deniz Işık Heves Surmeli Ozlem Nuray Sever Hatice Odabas Mahmut Emre Yıldırım Nedim Turan |
| author_sort | Sedat Yıldırım |
| collection | DOAJ |
| description | Abstract Background and Objectives Triple-negative breast cancer (TNBC) has a poor prognosis, and neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced TNBC. In this study, we aimed to evaluate the efficacy of adding carboplatin to NACT regarding pathological complete response (pCR) and survival in the HER2-low and HER2-zero subgroups of TNBC patients. Materials and Methods The study included 269 patients from five medical oncology clinics. Patients were divided into two groups: HER2-low (n = 152, 56.5%) and HER2-zero (n = 117, 43.5%). Among HER2-zero patients, 30 (25.6%) received carboplatin, while 38 (25.0%) HER2-low patients received carboplatin. The benefit of adding carboplatin to NACT regarding pCR and survival was assessed in both HER2-zero and HER2-low groups. Results When patients were evaluated according to HER2 status, the pCR rates were significantly higher in the HER2-zero group compared to the HER2-low group (45.2% versus 23.7%, p < 0.001). In the HER2-zero group, patients who received carboplatin had significantly higher pCR rates (63.3% versus 39.0%, p = 0.021). Similarly, in the HER2-low group, adding carboplatin significantly increased the pCR rates (36.8% versus 19.3%, p = 0.028). While carboplatin improved pCR rates in both HER2 subgroups, this benefit was not observed in patients with Grade 1 tumors, HER2 score 2-FISH negative tumors, or based on BRCA mutation status. Patients with pCR exhibited significantly prolonged DFS and OS (p = 0.002, p < 0.001, respectively). Conclusions Our research demonstrates that the addition of carboplatin increases pCR rates in both HER2-zero and HER2-low patient cohorts. We suggest that carboplatin should be considered as an addition to standard neoadjuvant chemotherapy for eligible TNBC patients, regardless of HER2-zero or HER2-low status, when appropriate based on individual patient factors and toxicity considerations. |
| format | Article |
| id | doaj-art-c2bde1e25d00476081203a28a66e9ca4 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-c2bde1e25d00476081203a28a66e9ca42025-08-20T03:53:22ZengBMCBMC Cancer1471-24072025-05-0125111210.1186/s12885-025-14252-3The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysisSedat Yıldırım0Tugba Başoğlu1Akif Doğan2Goncagul Akdağ3Oguzcan Kınıkoğlu4Alper Topal5Ozkan Alan6Ali Alper Solmaz7Mustafa Gürbüz8Timucin Çil9Rumeysa Çolak10Mesut Yılmaz11Ali Kalem12Nadiye Sever13Nargiz Majıdova14Kubilay Karakoyun15Serhat Sekmek16Omer Saçlı17Melike Ozcelık18Deniz Işık19Heves Surmeli20Ozlem Nuray Sever21Hatice Odabas22Mahmut Emre Yıldırım23Nedim Turan24Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Internal Medicine, Division of Medical Oncology, Gulhane Research & Training HospitalDivision of Medical Oncology, School of Medicine, Koç UniversityDepartment of Medical Oncology, Adana City HospitalDepartment of Medical Oncology, Adana City HospitalDepartment of Medical Oncology, Adana City HospitalMedical Oncology Department, Bakırköy Sadi Konuk Training and Research HospitalMedical Oncology Department, Bakırköy Sadi Konuk Training and Research HospitalDepartment of Medical Oncology, School of Medicine, Gaziantep UniversityDepartment of Medical Oncology, School of Medicine, Marmara UniversityDepartment of Medical Oncology, School of Medicine, Marmara UniversityMedical Oncology Department, Ağrı Training and Research HospitalDepartment of Medical Oncology, Ankara City HospitalDepartment of Medical Oncology, University of Health Sciences, Umraniye Training and Research HospitalDepartment of Medical Oncology, University of Health Sciences, Umraniye Training and Research HospitalDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science UniversityAbstract Background and Objectives Triple-negative breast cancer (TNBC) has a poor prognosis, and neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced TNBC. In this study, we aimed to evaluate the efficacy of adding carboplatin to NACT regarding pathological complete response (pCR) and survival in the HER2-low and HER2-zero subgroups of TNBC patients. Materials and Methods The study included 269 patients from five medical oncology clinics. Patients were divided into two groups: HER2-low (n = 152, 56.5%) and HER2-zero (n = 117, 43.5%). Among HER2-zero patients, 30 (25.6%) received carboplatin, while 38 (25.0%) HER2-low patients received carboplatin. The benefit of adding carboplatin to NACT regarding pCR and survival was assessed in both HER2-zero and HER2-low groups. Results When patients were evaluated according to HER2 status, the pCR rates were significantly higher in the HER2-zero group compared to the HER2-low group (45.2% versus 23.7%, p < 0.001). In the HER2-zero group, patients who received carboplatin had significantly higher pCR rates (63.3% versus 39.0%, p = 0.021). Similarly, in the HER2-low group, adding carboplatin significantly increased the pCR rates (36.8% versus 19.3%, p = 0.028). While carboplatin improved pCR rates in both HER2 subgroups, this benefit was not observed in patients with Grade 1 tumors, HER2 score 2-FISH negative tumors, or based on BRCA mutation status. Patients with pCR exhibited significantly prolonged DFS and OS (p = 0.002, p < 0.001, respectively). Conclusions Our research demonstrates that the addition of carboplatin increases pCR rates in both HER2-zero and HER2-low patient cohorts. We suggest that carboplatin should be considered as an addition to standard neoadjuvant chemotherapy for eligible TNBC patients, regardless of HER2-zero or HER2-low status, when appropriate based on individual patient factors and toxicity considerations.https://doi.org/10.1186/s12885-025-14252-3Triple negative breast cancerHER2 statusCarboplatinNeoadjuvant chemotherapyPathologic complete response |
| spellingShingle | Sedat Yıldırım Tugba Başoğlu Akif Doğan Goncagul Akdağ Oguzcan Kınıkoğlu Alper Topal Ozkan Alan Ali Alper Solmaz Mustafa Gürbüz Timucin Çil Rumeysa Çolak Mesut Yılmaz Ali Kalem Nadiye Sever Nargiz Majıdova Kubilay Karakoyun Serhat Sekmek Omer Saçlı Melike Ozcelık Deniz Işık Heves Surmeli Ozlem Nuray Sever Hatice Odabas Mahmut Emre Yıldırım Nedim Turan The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis BMC Cancer Triple negative breast cancer HER2 status Carboplatin Neoadjuvant chemotherapy Pathologic complete response |
| title | The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis |
| title_full | The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis |
| title_fullStr | The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis |
| title_full_unstemmed | The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis |
| title_short | The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis |
| title_sort | impact of carboplatin on pathologic complete response and survival based on her2 low and her2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy a multicenter real world analysis |
| topic | Triple negative breast cancer HER2 status Carboplatin Neoadjuvant chemotherapy Pathologic complete response |
| url | https://doi.org/10.1186/s12885-025-14252-3 |
| work_keys_str_mv | AT sedatyıldırım theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT tugbabasoglu theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT akifdogan theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT goncagulakdag theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT oguzcankınıkoglu theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alpertopal theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT ozkanalan theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alialpersolmaz theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mustafagurbuz theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT timucincil theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT rumeysacolak theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mesutyılmaz theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alikalem theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nadiyesever theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nargizmajıdova theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT kubilaykarakoyun theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT serhatsekmek theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT omersaclı theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT melikeozcelık theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT denizisık theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT hevessurmeli theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT ozlemnuraysever theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT haticeodabas theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mahmutemreyıldırım theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nedimturan theimpactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT sedatyıldırım impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT tugbabasoglu impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT akifdogan impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT goncagulakdag impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT oguzcankınıkoglu impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alpertopal impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT ozkanalan impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alialpersolmaz impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mustafagurbuz impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT timucincil impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT rumeysacolak impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mesutyılmaz impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT alikalem impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nadiyesever impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nargizmajıdova impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT kubilaykarakoyun impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT serhatsekmek impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT omersaclı impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT melikeozcelık impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT denizisık impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT hevessurmeli impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT ozlemnuraysever impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT haticeodabas impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT mahmutemreyıldırım impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis AT nedimturan impactofcarboplatinonpathologiccompleteresponseandsurvivalbasedonher2lowandher2zerostatusintriplenegativebreastcancerpatientsreceivingneoadjuvantchemotherapyamulticenterrealworldanalysis |